Abstract
Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Volume: 8 Issue: 3
Author(s): Jun Sun
Affiliation:
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Abstract: Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Export Options
About this article
Cite this article as:
Sun Jun, Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151986
DOI https://dx.doi.org/10.2174/187152309789151986 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elucidating Protein-protein Interactions Through Computational Approaches and Designing Small Molecule Inhibitors Against them for Various Diseases
Current Topics in Medicinal Chemistry Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Current Vascular Pharmacology 3-(1-Adamantylthio)-4-Phenylpyridine as a Potential Therapeutic for Methicillin-Resistant Staphylococcus aureus
Letters in Drug Design & Discovery Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Chemistry and Pharmacology of Neglected Helminthic Diseases
Current Medicinal Chemistry Recent Advances in Analytical Techniques used for the Determination of Fluoroquinolones in Pharmaceuticals and Samples of Biological Origin - A Review Article
Current Pharmaceutical Analysis Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Small Molecule Approaches Toward the Non-Microbicidal Modulation of Bacterial Biofilm Growth and Maintenance
Anti-Infective Agents in Medicinal Chemistry ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology 3rd Generation of Cephalosporins and Monobactam Resistant Among Pathogenic Bacteria Collected from Ilam Hospitals During 2008 to 2015: A Systematic Review and Meta-Analysis
Recent Patents on Anti-Infective Drug Discovery <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Antibiotic Prophylaxis in Urologic Prosthetic Surgery
Current Pharmaceutical Design Biofilms and their Role in the Resistance of Pathogenic Candida to Antifungal Agents
Current Drug Targets Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Odontogenic Infections in the Etiology of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses